Neurocrine Biosciences (NBIX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$142.70-0.41%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Neurocrine Biosciences’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.8%

+10% or more+5%0%−5%−10% or less

9.71 → 9.63 EPS · FY ending Dec 31, 2027 · 15 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 15 to 15; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	1.08B
EPS	—	1.941
FY 2026 · Annual
Revenue	—	3.9B
EPS	—	7.15
R&D	About $25M	—
FY 2027 · Annual
Revenue	—	4.52B
EPS	—	9.633

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage debt from acquisition and secure $1 billion credit facility	A supporting condition in Neurocrine Biosciences's published investment case. The stated target is Credit facility secured and manageable debt levels.	Intact	Debt levels become unsustainable or credit facility not secured	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Sustain strong growth for INGREZZA and CRENESSITY	A primary condition in Neurocrine Biosciences's published investment case. The stated target is Revenue growth >= 28% YoY.	Intact	Revenue growth falls below 20% YoY in FY26	Revenue growth: 39.49% FY2026-Q2; GAAP. Published target: Revenue growth >= 28% YoY. Target period is not explicitly aligned with this observation. Source published Jul 30, 202639.490909 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 1bbcc37d-f529-4f2c-9f46-cb26e200c21b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue near $2.75 billion in 2026	A primary condition in Neurocrine Biosciences's published investment case. The stated target is ~$2.75 billion.	Intact	Revenue falls below $2.5 billion in FY26	Revenue: $959M FY2026-Q2; GAAP. Published target: ~$2.75 billion. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026959,000,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 1bbcc37d-f529-4f2c-9f46-cb26e200c21b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Complete Soleno acquisition to expand rare disease portfolio	The Soleno acquisition expands rare disease products.	Intact	Acquisition fails or is reversed	Acquisition completed 2026-05-18 vs mid-2026 target May 18, 2026 8-K confirms the closing of the Soleno merger, satisfying the acquisition completion driver. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The acquisition of Soleno Therapeutics was announced in 2026-Q1, completed in 2026-Q2, and integrated with VYKAT XR contributing $54 million in net product sales in Q2 2026. Management is delivering on the acquisition and integration as planned. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$9.63

$12.66 → $9.63 · observed estimates

FY2027 revenue$4.52B

$4.49B → $4.52B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$12.66	$4,487,542,430	15 / 23
2026-07-25	$12.66	$4,494,291,950	15 / 22
2026-07-26	$9.99	$4,421,579,521	14 / 18
2026-07-27	$9.99	$4,421,579,521	14 / 18
2026-07-28	$12.66	$4,494,291,950	15 / 22
2026-07-29	$12.66	$4,494,291,950	15 / 22
2026-07-30	$10.01	$4,419,110,290	14 / 17
2026-07-31	$9.86	$4,447,771,402	14 / 18
2026-08-01	$9.86	$4,447,771,402	14 / 18
2026-08-02	$12.18	$4,568,440,160	17 / 23
2026-08-03	$9.79	$4,505,857,805	14 / 18
2026-08-04	$12.18	$4,568,440,160	17 / 23
2026-08-05	$9.79	$4,505,857,805	14 / 18
2026-08-06	$9.79	$4,505,857,805	14 / 18
2026-08-07	$9.79	$4,505,857,805	14 / 18
2026-08-08	$12.17	$4,568,440,160	17 / 23
2026-08-09	$12.17	$4,568,440,160	17 / 23
2026-08-10	$12.17	$4,568,440,160	17 / 23
2026-08-12	$12.17	$4,568,440,160	17 / 23
2026-08-13	$12.17	$4,568,440,160	17 / 23
2026-08-14	$9.79	$4,505,857,805	14 / 18
2026-08-15	$9.79	$4,505,857,805	14 / 18
2026-08-16	$9.79	$4,505,857,805	14 / 18
2026-08-17	$9.79	$4,505,857,805	14 / 18
2026-08-18	$9.79	$4,505,857,805	14 / 18
2026-08-19	$9.79	$4,505,857,805	14 / 18
2026-08-20	$9.75	$4,529,820,755	14 / 18
2026-08-21	$9.75	$4,529,820,739	14 / 18
2026-08-22	$9.75	$4,529,820,739	14 / 18
2026-08-23	$9.75	$4,529,820,739	14 / 18
2026-08-24	$9.75	$4,529,820,739	14 / 18
2026-08-25	$9.75	$4,529,820,739	14 / 18
2026-08-26	$9.75	$4,529,820,739	14 / 18
2026-08-27	$9.75	$4,529,820,739	14 / 18
2026-08-28	$9.75	$4,529,820,739	14 / 18
2026-08-29	$9.75	$4,500,585,787	14 / 18
2026-08-30	$9.75	$4,500,585,787	14 / 18
2026-08-31	$9.75	$4,500,585,787	14 / 18
2026-09-01	$9.75	$4,500,585,787	14 / 18
2026-09-02	$9.75	$4,500,585,787	14 / 18
2026-09-03	$9.75	$4,500,585,787	14 / 18
2026-09-04	$9.75	$4,500,585,787	14 / 18
2026-09-05	$9.75	$4,502,932,857	14 / 18
2026-09-06	$9.75	$4,502,932,857	14 / 18
2026-09-07	$9.75	$4,502,932,857	14 / 18
2026-09-08	$9.75	$4,502,932,857	14 / 18
2026-09-09	$9.75	$4,502,952,315	14 / 18
2026-09-10	$9.75	$4,502,952,315	15 / 18
2026-09-11	$9.75	$4,502,952,315	15 / 18
2026-09-12	$9.75	$4,502,952,315	15 / 18
2026-09-13	$9.75	$4,502,952,315	15 / 18
2026-09-14	$9.75	$4,502,952,315	15 / 18
2026-09-15	$9.75	$4,502,952,315	15 / 18
2026-09-16	$9.75	$4,502,952,315	15 / 18
2026-09-17	$9.75	$4,502,965,094	15 / 18
2026-09-18	$9.75	$4,502,965,094	15 / 18
2026-09-19	$9.75	$4,502,965,094	15 / 18
2026-09-20	$9.75	$4,502,965,094	15 / 18
2026-09-21	$9.75	$4,502,965,094	15 / 18
2026-09-22	$9.75	$4,502,965,094	15 / 18
2026-09-23	$9.71	$4,497,734,511	15 / 18
2026-09-24	$9.71	$4,497,734,511	15 / 18
2026-09-25	$9.71	$4,497,734,511	15 / 19
2026-09-26	$9.71	$4,497,734,511	15 / 19
2026-09-27	$9.71	$4,497,734,511	15 / 19
2026-09-28	$9.71	$4,497,734,511	15 / 19
2026-09-29	$9.64	$4,498,988,596	15 / 19
2026-09-30	$9.64	$4,498,988,596	15 / 19
2026-10-01	$9.64	$4,498,988,595	15 / 19
2026-10-02	$9.64	$4,498,988,595	15 / 19
2026-10-03	$9.64	$4,498,988,595	15 / 19
2026-10-04	$9.64	$4,498,988,595	15 / 19
2026-10-05	$9.64	$4,498,988,595	15 / 19
2026-10-06	$9.64	$4,498,988,595	15 / 19
2026-10-07	$9.64	$4,498,988,595	15 / 19
2026-10-08	$9.64	$4,498,988,595	15 / 19
2026-10-09	$9.64	$4,501,227,512	15 / 19
2026-10-10	$9.64	$4,501,227,512	15 / 19
2026-10-11	$9.66	$4,501,227,512	15 / 19
2026-10-12	$9.66	$4,501,227,512	15 / 19
2026-10-13	$9.72	$4,519,276,995	15 / 19
2026-10-14	$9.72	$4,519,276,037	15 / 18
2026-10-15	$9.72	$4,519,276,037	15 / 18
2026-10-16	$9.72	$4,519,276,037	15 / 18
2026-10-17	$9.72	$4,519,276,037	15 / 18
2026-10-18	$9.72	$4,520,242,704	15 / 18
2026-10-19	$9.72	$4,520,242,704	15 / 18
2026-10-20	$9.72	$4,520,242,704	15 / 18
2026-10-21	$9.67	$4,520,155,037	15 / 18
2026-10-22	$9.67	$4,520,155,037	15 / 18
2026-10-23	$9.67	$4,520,155,037	15 / 18
2026-10-24	$9.63	$4,520,155,037	15 / 18

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	24	4
2026-06-01	25	4
2026-07-01	25	4
2026-08-01	24	4
2026-09-01	25	4
2026-10-01	25	4

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 25 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSSep 29 · prior Jun 30

$208.00 → $214.00+2.9%

$0$117.70$235.40

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage debt from acquisition and secure $1 billion credit facilityQualitative condition
Sustain strong growth for INGREZZA and CRENESSITYRevenue growth: 39.49%
Achieve revenue near $2.75 billion in 2026Revenue: $959M

Next proof point

Nov 2, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.0%Typical daily move · historical

Downside history

-27.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Neurocrine Biosciences outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

NBIX is a growth-oriented healthcare business, with recent growth from INGREZZA, CRENESSITY, and VYKAT XR. Its one-to-three-year thesis is intact, and recent financial performance remains in the top half of its industry. Management is on track with commercial growth and Soleno integration, while pipeline execution is mixed.

What's priced into Neurocrine Biosciences

The evidence describes NBIX as cheap versus peers, but also reports an 0.82 premium versus peers and an expectations gap of -0.58. These valuation signals are mixed, so the overall priced-in tag is justified rather than clearly cheap or expensive. The model has medium confidence, and no fragility gates have fired.

What the fundamentals likely do

Near term, revenue growth has been strong: second-quarter 2026 revenue was up 39% year over year, and VYKAT XR contributed $54 million in net product sales after the Soleno acquisition. Management raised guidance on July 30, 2026, and the latest event was an earnings beat, though the evidence flags a possible credibility risk if guidance is later cut. Over the multi-year view, Phase 3 programs are advancing with increased research spending, but pipeline progress is mixed and industry peers have recently missed.

What Neurocrine Biosciences hinges on

The key company-specific test is whether NBIX sustains growth and avoids reversing its recently raised guidance. The broader setting also matters: weakening jobs data could weigh on healthcare names, while continued strong results and higher guidance from sector bellwethers such as VRTX, REGN, and MRNA could support sector momentum. Evidence on the pipeline is limited to steady progress and mixed status, so its longer-term contribution remains uncertain.